PHARMACEUTICAL 2017

Macrogenics INC
Rank 42 of 308



PHARMACEUTICAL 2017

Macrogenics INC
Rank 42 of 308

The relative strengths and weaknesses of Macrogenics INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Macrogenics INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 92% points.The greatest weakness of Macrogenics INC is the variable Research and Development, reducing the Economic Capital Ratio by 15% points.

The company's Economic Capital Ratio, given in the ranking table, is 367%, being 123% points above the market average of 245%.

Input Variable	Value in 1000 USD
Assets, Current	283,947
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	27,302
Liabilities, Non-Current	0
Other Assets	9,355
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	15,210
Other Net Income	1,514
Other Revenues	91,880
Property and Equipment	17,961
Research and Development	122,091
Selling, General and Administrative Expense	29,831

Output Variable	Value in 1000 USD
Assets	311,263
Liabilities	42,512
Expenses	151,922
Revenues	91,880
Stockholders Equity	268,751
Net Income	-58,528
Comprehensive Net Income	-58,528
BaseVar	299,546
ECR before LimitedLiability	298%
Economic Capital Ratio	367%